CAP Submits Comments on Proposed 2027 Medicare Physician Fee Schedule
The College of American Pathologists (CAP) submitted comments to the proposed 2027 Medicare Physician Fee Schedule (PFS), addressing proposals that...
The U.S. Food and Drug Administration (FDA) formally rescinded its final rule regulating laboratory-developed tests as medical devices, and regulatory review is now pending. Because the FDA did not move to appeal this decision, the rescission is essentially a formality.
The recission comes following the decision filed March 31 in the U.S. District Court in the Eastern District of Texas, which ruled the FDA exceeded its authority and subsequently vacated the final rule. The FDA did not appeal this decision.
Once the Office of Information and Regulatory Affairs completes the regulatory review, a formal notice will be posted to the Federal Register within 60 days.
Sources:
https://www.reginfo.gov/public/do/eoDetails?rrid=1044563
https://documents.cap.org/documents/ldt-courtruling-03-31-2025.pdf
https://www.cap.org/advocacy/latest-news-and-practice-data/august-12-2025#story3
CMS Announces Phased-In Reduction of Medicare Payment Rates for Lab Services
The Centers for Medicare & Medicaid Services (CMS) plans to reduce preliminary Medicare payment rates for laboratory services.
UHC to Eliminate Certain Prior Authorization Requirements Across Plans
United Healthcare announced Sept. 1 it is eliminating 30 percent of prior authorization requirements for certain plans.